Protalix BioTherapeutics, Inc
Price
FilingsNewest: Form 10-Q, quarterly reportNov 10 →Insiders1 insider bought $101,360 in 1 open-market buy. No sales.→HoldersBlackRock 5.0%Renaissance Technologies 1.4%State Street 1.2%→Financing →PeersClosest companies: PTCT, AZTR, RARE→
From the filings
Figures
- Revenue
- $84.7Mlast 12 months
- Net income
- $20.6Mlast 12 months
- Operating cash flow
- $9.9Mlast 12 months
- Cash and equivalents
- $22.0Mat the last balance sheet
- Shares outstanding
- 80.4M shareson issue
Filings, newest first
- Nov 1010-QQuarterly report
- Nov 108-KResults of operations
- Oct 1513GStake over 5%, passive
- Sep 94Insider trade
- Aug 1210-QQuarterly report
- Aug 128-KResults of operations
- Jul 2913GStake over 5%, passive
- Jun 258-KShareholder vote
- May 218-KRegulation FD disclosure
- Mar 1810-KAnnual report
- Dec 23, 20254Insider trade